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Identiﬁcation of genetic copy number changes in glial
tumors is of importance in the context of improved/reﬁned
diagnostic, prognostic procedures and therapeutic deci-
sion-making. In order to detect recurrent genomic copy
number changes that might play a role in glioma
pathogenesis and/or progression, we characterized 25
primary glioma cell lines including 15 non glioblastoma
(non GBM) (I–III WHO grade) and 10 GBM (IV WHO
grade), by array comparative genomic hybridization,
using a DNA microarray comprising approx. 3500 BACs
covering the entire genome with a 1Mb resolution and
additional 800 BACs covering chromosome 19 at tiling
path resolution. Combined evaluation by single clone and
whole chromosome analysis plus ‘moving average (MA)
approach’ enabled us to conﬁrm most of the genetic
abnormalities previously identiﬁed to be associated with
glioma progression, including þ 1q32, þ 7, 10, 22q,
PTEN and p16 loss, and to disclose new small genomic
regions, some correlating with grade malignancy. Grade
I–III gliomas exclusively showed losses at 3p26 (53%),
4q13–21 (33%) and 7p15–p21 (26%), whereas only
GBMs exhibited 4p16.1 losses (40%). Other recurrent
imbalances, such as losses at 4p15, 5q22–q23, 6p23–25,
12p13 and gains at 11p11–q13, were shared by different
glioma grades. Three intervals with peak of loss could be
further reﬁned for chromosome 10 by our MA approach.
Data analysis of full-coverage chromosome 19 highlighted
two main regions of copy number gain, never described
before in gliomas, at 19p13.11 and 19q13.13–13.2. The
well-known 19q13.3 loss of heterozygosity area in gliomas
was not frequently affected in our cell lines. Genomic
hotspot detection facilitated the identiﬁcation of
small intervals resulting in positional candidate genes
such as PRDM2 (1p36.21), LRP1B (2q22.3), ADARB2
(10p15.3), BCCIP (10q26.2) and ING1 (13q34) for losses
and ECT2 (3q26.3), MDK, DDB2, IG20 (11p11.2) for
gains. These data increase our current knowledge about
cryptic genetic changes in gliomas and may facilitate the
further identiﬁcation of novel genetic elements, which may
provide us with molecular tools for the improved
diagnostics and therapeutic decision-making in these
tumors.
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Introduction
Gliomas are the most frequently occurring primary
brain tumors in humans, and can be subdivided into
three histological subtypes, that is, astrocytoma, oligo-
dendroglioma and mixed oligoastrocytoma (OA), each
characterized by a different grade of malignancy
according to the WHO classiﬁcation (Kleihues and
Cavenee, 2000). Despite recent technical improvements
in radiological and pathological diagnostic procedures,
as well as the increasing knowledge on glioma biology
and genetics, the possibilities for effective treatment and
prognosis remain poor, especially for patients affected
by glioblastoma (GBM) (the most aggressive astrocytic
form), who have an average survival of o1 year after
diagnosis (Simpson et al., 1993). At the other side of the
prognostic spectrum, oligodendroglial tumors exhibiting
loss of chromosomal arms 1p and/or 19q show a better
response to chemotherapy and, consequently, a better
prognosis (Cairncross et al., 1998; Ino et al., 2001;
Jeuken et al., 2004).
Difﬁculties in clinical management (e.g. treatment and
prognosis) are related to the complex identity of
gliomas, which impairs a clearcut classiﬁcation needed
for discrimination between different tumor subtypes.
Limitations of the actual diagnostic criteria are pointed
out by data on both the different combinations of
genetic lesions in tumors sharing similar histology, grade
and intratumor genetic heterogeneity (Noble and
Dietrich, 2004). For these reasons, there is a growing
awareness that genome-wide and high-resolution genetic
analyses will contribute to the improvement of the
Received 7 April 2005; revised 9 August 2005; accepted 9 September
2005; published online 24 October 2005
Correspondence: Professor L Larizza, Department of Biology and
Genetics for Medical Sciences, University of Milan, Via Viotti 3/5,
Milano 20133, Italy.
E-mail: lidia.larizza@unimi.it
Oncogene (2006) 25, 1571–1583
& 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00
www.nature.com/onc
O
N
C
O
G
E
N
O
M
IC
S
current WHO classiﬁcation by constructing a more
objective molecular taxonomy of gliomas (Mischel et al.,
2004).
For this purpose, over the last decade molecular
approaches including mutation screening, comparative
genomic hybridization (CGH) and loss of heterozygo-
sity (LOH) analyses have led to the identiﬁcation of the
most frequently recurring genomic imbalances correlat-
ing to each WHO subtype (Koschny et al., 2002;
Shapiro, 2002; Kitange et al., 2003) and to the
identiﬁcation of several genes acting in pathways
involved in glioma development, either in the initiation
stages (p53 and Ras by PDGF-NF1) or in malignant
progression (Rb-CDKN2-CDK4) (Zhu and Parada,
2002; Collins, 2004). Deletion of 19q is of particular
interest, as it is shared by all three glioma subtypes,
occurring in approximately 75% of oligodendroglioma,
45% of mixed OA and 40% of astrocytoma (von
Deimling et al., 1992, 1994), where it is associated with
the transition from low-grade to anaplasic tumors
(Ohgaki et al., 1995; Ritland et al., 1995; Smith et al.,
1999). Furthermore, similarly to oligodendroglioma,
combined LOH of 1p and 19q was found to deﬁne a
small subset of GBM patients with a signiﬁcantly better
survival, even if their tumors are not morphologically
distinguishable from the bulk of GBMs (Schmidt et al.,
2002).
A candidate tumor suppressor region has been
assigned by LOH studies to 19q13.3, but no prime
positional functional candidate gene in this band has yet
been identiﬁed (Hartmann et al., 2002). We postulated a
possible role for the novel serine threonine kinase gene
MARK4, which maps at the centromeric boundary of
the 19q13.3 LOH region, and which is overexpressed
and duplicated in three GBM cell lines (Beghini et al.,
2003).
In order to improve our current knowledge on both
gross and subtle genetic changes involved in glioma
initiation and progression, we interrogated 25 primary
cell lines at the whole genome level by array-based
comparative genomic hybridization (array-CGH or
aCGH) at a 1Mb resolution. Since chromosome 19 is
of particular interest in the context of clinical decision-
making, a full genomic chromosome 19 tiling path was
also present on our arrays (our current resolution on
chromosome 19 is in theory around 50 kb, and in
practice around 100 kb).
Few high-resolution aCHG studies on gliomas are
currently available to complement previously published
CGH, SKY and LOH analyses (Cowell et al., 2004a, b;
Bredel et al., 2005; Kitange et al., 2005; Nigro et al.,
2005), which have all demonstrated an excellent
correlation between the ﬁndings obtained through this
approach, and those obtained by alternative techniques,
stressing the usefulness and overall accuracy of this
genomic approach as compared to classic most widely
employed analyses (Cowell et al., 2004a, b).
Comparative analysis of elaborated aCGH data
obtained on our cell lines collection allowed us to
identify copy number changes shared by various glioma
grades as well as aberrations apparently related to
progression to GBM. Besides the conﬁrmatory copy
number alterations previously identiﬁed in gliomas, we
also identiﬁed several genomic intervals containing
novel candidate genes involved in gliomagenesis and/
or progression recurrently found to be affected. Further
clinical validation of these intervals by dedicated
approaches might enable their inclusion among the
genetic markers useful for a prognostic classiﬁcation of
gliomas, and is expected to ultimately lead to improved
clinical decision-making.
Results
Recurrent genomic imbalances
Aiming at the detection of recurrent genomic copy
number changes involved in glioma genesis and/or
progression, we characterized 15 grade I–III gliomas
(deﬁned as ‘non-GBMs’) and 10 GBMs primary cell
lines (Supplementary Table A) by aCGH on a 3.5k
whole genome plus full-coverage chromosome 19 BAC
array. Figure 1 depicts all the autosome ideograms
(except chromosome 19, which is shown separately and
in more detail in Figure 3) with the corresponding copy
number changes identiﬁed in each cell line by the
combined application of two statistical approaches: the
whole chromosome association analysis and the ‘moving
average (MA)’ algorithm. Whole chromosome associ-
ation analysis deﬁnes entirely gained or lost chro-
mosomes (Hackett et al., 2003), whereas the ‘MA
algorithm’ allowed us to cluster gained or lost clones
with aberrant average ratios in consecutive areas of copy
number changes (Schraders et al., 2005). For more
deﬁned regions affecting at least four cases of partial
chromosomal arm imbalance, the smallest regions of
overlap (SROs), deﬁned as the minimal regions of
deletion/gain overlap, were also determined as shown in
Table 1, where detailed clone information as well as the
physical location (Mb positions) of the encompassing
and ﬂanking clones is also provided.
Figure 1 and Table 1 show genomic imbalance
affecting either speciﬁcally GBMs or non-GBMs
or, alternatively, both. The most frequent changes
exclusive for GBMs involve complete or partial gain
of chromosome 7 (70%), loss of chromosomes 10
(100%) and 22 (40%) (Kitange et al., 2003), which
are known to be involved in glioma progression, as
well as gain at 1q32 (Riemenschneider et al., 2003),
detected in three GBMs and in one non-GBM. We also
identiﬁed novel recurrent ﬁndings unreported in pre-
vious studies. We found that only GBMs show loss of
chromosome 18 (40%) and gain of the entire chromo-
some 21 (50%). Double I-FISH using two chromosome
21 BACs lyingB7Mb apart from each other conﬁrmed
the aCGH gain in showing a very high number (>8)
of signals for both probes in the great majority
of nuclei of the representative MI-7 cell line (chromo-
some 21 average log2 ratio¼ þ 0.3) (see Supplementary
Figure A).
A small overlapping region mapping at 4p16.1 is
also speciﬁcally lost in four (40%) GBM cell lines.
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Figure 1 Copy number changes as identiﬁed by statistical analysis of the aCGH data. All chromosome ideograms are depicted, with
the exceptions of sex chromosomes (not included in the analysis), and chromosome 19, which is shown at increased resolution in
Figure 3. Bars of different color for ‘non-GBMs’ (red) and GBMs (blue) are placed on the right and on the left of each chromosome
ideogram to indicate both gains and losses, respectively.
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Three SROs mapping at 3p26, 4q13–21 and 7p15–21
turn out to be exclusively lost in, respectively, eight
(53%), ﬁve (33%) and four (26%) of non-GBMs,
whereas both glioma groups share partial losses at
4p15, 5q, 6p and 12 p and gains at 11p–q (Table 1).
In addition, the use of the ‘MA’ algorithm allowed us
to estimate which areas are quantitatively more involved
within entirely gained or lost chromosomes such as
chromosomes 10 and 7, the two most frequent aberra-
tions found in gliomas. As depicted in Figure 1, seven
GBM cell lines showed loss of the entire chromosome
10. As shown in Figure 2, three distinct areas emerged in
all cell lines by using this algorithm. The three areas on
chromosome 10 encompass several candidate tumor
suppressor genes, including KLF6, LGI1, PTEN,
DMBT1, WDR11 and MXI1, already known to be
indeed associated with glioma progression (Chernova
et al., 2001; Manni et al., 2002; Kohler et al., 2004). One
region spans from 10pter to 10p14, with a peak between
clones RP11-89B19 and RP11-80D10 at 10p15.3
telomerically to KLF6; only the ADARB2 gene, a
brain-speciﬁc adenosine deaminase, resides within this
interval. The second interval, mapping at 10q22.2–
10q23.33, shows a peak of loss at 10q22.3, centromeri-
cally to PTEN between clones RP11-45P20 and RP11-
342M3 and includes ﬁve annotated genes. The third
region, spanning 10q25–26, has a peak at 10q26.13–
q26.2 between clones RP11-70E19 and RP11-32H11 and
telomeric to DMBT1: the peak loss area comprises 12
fully assigned genes.
When chromosome 7 was tested by the same
approach, a homogeneous trend of imbalance along
the entire chromosome was revealed, and no recurrent
areas with signiﬁcant deviation from whole chromosome
average could be detected (data not shown).
DNA copy number changes detected by the full
chromosome 19 coverage subarray
Motivated by the frequent involvement of chromosome
19q in gliomas (von Deimling et al., 1992, 1994; Ohgaki
et al., 1995; Ritland et al., 1995; Smith et al., 1999;
Schmidt et al., 2002) and our recent data on the
duplication ofMARK4 in three GBM cell lines (Beghini
et al., 2003), we pursued a high-resolution characteriza-
tion of chromosome 19 in our cell lines through the use
of full genomic coverage aCGH for this particular
chromosome.
By applying the ‘MA’ algorithm, two frequently
gained regions of interest, mapping to 19p13.11 and
19q13.13–13.2, respectively, emerged, for each of which
a SRO could be deﬁned (Figure 3).
The 19p13.11 interval, with a SRO spanning
about 350 kb (from RP11-365K12 to RP11-350I20)
encompasses 13 genes and was gained in three non-
GBM and four GBM cell lines. The 19q13.13–13.2
interval was gained in three non-GBM and four
GBM cell lines too. This latter 630 kb interval (from
RP11-1031M21 to RP11-452P05) contains 16 genes.
Moreover, we were able to detect at 19p13.2 (8.55–
8.81Mb) a region of copy number changes (lost and
gained) in 20 cell lines as well in three normal versus
normal hybridizations. By further analysis, we could
establish that copy number changes behaved in a
‘hybridization reference-dependent’ way (data not
shown), conﬁrming its polymorphic nature, consistent
with the information on clone RP11-79F15 provided by
the Genome Variation Database (http://projects.tcag.
ca.variation) (Iafrate et al., 2004; Sebat et al., 2004). In
our normal controls, the largest polymorphic region
spans 260 kb, and is located between clones RP11-92E05
and RP11-203K06.
Table 1 Smallest regions of overlapping imbalances (SROs) shared by at least four cases of partial chromosomal arm gain/loss
Chr. Gain/loss Upper ﬂanking clone Lower ﬂanking clone Physical interval (Mb) Cytogenetic interval Incidence
10GBMs
15 non-GBMs
1q Gain RP11-148K15 RP11-145I13 201.30–203.75 1q32.1 1 non-GBM
3 GBMs
3p Loss RP11-121D3 RP11-32F23 2.21–4.19 3p26.1–p26.3 8 non-GBMs
4p Loss Rp11-97H19 RP11-34C20 6.87–11.01 4p16.1 4 GBMs
4p Loss RP11-89H17 RP11-151G21 17.28–20.12 4p15.31–p15.32 1 non-GBMs
3 GBMs
4q Loss RP11-234L24 RP11-105F22 67.57–77.45 4q13.2–q21.1 5 non-GBMs
5q Loss RP11-64F17 RP11-45L19 112.71–128.33 5q22.2–q23.3 7 non-GBMs
1 GBM
6p Loss RP11-53P21 RP11-83B17 1.41–14.55 6p23–p25.3 11 non-GBMs
1 GBMs
7p Loss RP11-123E5 RP11-243C6 17.33–22.68 7p15.3–p21.1 4 non-GBMs
11 Gain RP11-29O22 RP11-20K4 46.58–67.22 11p11.2–q13.2 3 non-GBMs
3 GBMs
12p Loss RP11-96B19 RP11-72J9 11.74–14.23 12p13.1–p13.2 3 non-GBMs
5 GBMs
Mb position and chromosome bands of the clones are as listed by the UCSC genome browser (May 2004 freeze).
Array-based CGH in glioma cell lines
G Roversi et al
1574
Oncogene
By means of the ‘MA’ algorithm, we also found that
the interval characterized by ﬁve overlapping clones,
and containing the entire MARK4 gene, belongs to a
region of gain in three non-GBM (MI-67, MI-26, G43)
and one GBM (MI-4) cell lines. Moreover, a GBM cell
line (MI-63) showed a gained region partially included
in the MARK4 overlapping clones, while only one non-
GBM cell line (MI-13, AOA) presented a deletion in the
candidate tumor suppressor region 19q13.3 stretching to
MARK4. The SRO gained region, placed at the
centromeric boundary of LOH tumor suppressor area
(Figure 3), is comprised between clones RP11-752G09
and CTD-2344L03, where, besidesMARK4, the creatine
kinase, CKM, kinesin light chain, KLC2, the DNA
repair genes, ERCC1 and 2, the inhibitor of p53
function, PPP1R13L, and the nucleolar autoantigen
gene, ASE-1, reside.
Single clone analysis
A total of 29 homozygously deleted clones (log2
ratioo0.8) were identiﬁed in eight GBM cell lines
(Table 2), whereas grade I–III glioma cell lines did not
reveal any homozygously deleted clones. In all, 14 clones
mapping to 12p12.1–p13.32 belong to a rather large
(B23Mb) area of deletion in the G32 cell line and a few
reside in the previously described 12p SRO (Table 1). As
the G32 cell line shows by aCGH the loss of the entire
chromosome 12, in order to conﬁrm that 12p13.1
(targeted by clone RP11–439G16, log2 ratio 0.85) is
under-represented as compared to 12q (monitored by
clone RP11–141F8, log2 ratio 0.25), we performed
dual color I-FISH to evaluate the ratio between the
number of signals given by the two clones. Scoring of
100 nuclei revealed that the ratio of 12q:12p copies as
determined by aCGH (1.68:1.10¼ 1.52) underestimated
the ratio obtained by FISH (1.95) (see Supplementary
Figure B). Only clone CTD-2154O24 mapping to
chromosome 9p21 appeared to be deleted in more than
one GBM cell line (MI-7 and MI-4) and contains the
CDKN2A (p16) gene, a well-known tumor suppressor
gene known to be involved in glioma progression (Zhu
and Parada, 2002). Chromosomes 10 and 22 show
multiple regions of homozygous deletions. More speci-
ﬁcally, clone RP11-129G17, which resides at 10q23 and
ﬂanks the PTEN gene, which is known to be of
functional relevance in gliomas (Zhu and Parada,
2002; Rong et al., 2005), is homozygously deleted. In
addition, two clones mapping to 10q26.2, although not
consecutive, probably delimit the same deletion in cell
line MI-63, as two clones between them present log2
ratioo0.5. The observation of discontinuous intervals
may be explained by ambiguous mapping positions,
subject to change upon release of future, revised
genome-builds. Indeed, most nuclei (92/100) of the
MI-63 cell line did not show any hybridization signal
following I-FISH with the RP11-32H11 clone labeled
either by green or red ﬂuorescence (see Supplementary
Figure C).
By comparing the frequencies of the most frequently
heterozygously deleted clones (log2 ratioo0.3) among
15 non-GBMs and 10 GBMs (Table 3), a picture
Figure 2 Most extreme moving average intervals on chromosome 10. Chromosomal bands and moving average values are depicted on
the X- and Y-axis, respectively. Each cell line is marked by a different color and in the caption the corresponding whole chromosome
average values are reported. Gray boxes indicate the peaks of the most extreme moving average. The map position of most fully
annotated tumor suppressors and candidate tumor suppressors is indicated.
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emerges in which both glioma groups share
high-frequency deletions for the clone RP11-709A23 at
12p11.23, whereas other clones are exclusively involved
in one of the two histological subgroups. Among these,
clones mapping to 3p26 and 4q13.3, which fall in the
previously described SROs (a), stand out among non-
GBMs, just as clones mapping at 12p13.1 (RP11-
439G16 and RP11-1092P21), sorted also as homozygous
deletions (c), emerge among GBMs.
We did not detect any clones with ampliﬁed
signal intensities (log2 ratio >1), whereas gained
clones showing a log2 ratio’s between 0.5 and 1 (Table 4)
were detected for 31 clones in I–III grade gliomas,
and for 201 clones in GBMs. The majority maps
to chromosome 7, belongs to cell lines with additional
chromosome(s) 7 and is not involved in non-GBM
cell lines, with the exception of RP5-953A4 at
7q11.23, which is gained in one non-GBM cell
line too, and RP11-1143D24 at 19q12, which, to our
knowledge, does not contain any annotated gene.
Non-GBMs speciﬁc clones are nearly all listed
as polymorphic clones in the Genome Variation
Database (http://projects.tcag.ca.variation) (Iafrate
et al., 2004; Sebat et al., 2004) and were all gained in
GBM cell lines too. Gain signals with log2 ratio>0.3
(Table 5) were shared by both GBMs and non-GBMs
for clone RP11-39G12, which, together with the
polymorphic clone RP11–79A4, belongs to the 11p–q
SRO previously identiﬁed by our MA approach
(Table 1).
Figure 3 Chromosome 19 imbalance detected by full-coverage array. Each vertical line on the X-axis corresponds to a cell line. Mb
position and chromosome bands are shown on the Y-axis. Losses are depicted in red, and gains in green. Gray lines indicate the SRO
regions at 19p13.11, 19q13.13–13.2 and LCV at 19p13.2. MARK4 clones at 19q13.3 are also indicated. Magniﬁcation of the region
spanned by ﬁve overlapping clones (gray area) and entirely covering the MARK4 gene is shown on the right.
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Table 3 Most frequently heterozygous deleted clones (log2 ratio o0.3)
Clone name Chr. band Mb position % Non-GBMs % GBMs Annotated genes
RP11–178M15 1p36.21 13.73 35 (5/14) / T1A-2, PRDM2
RP11–32F23a 3p26 4.16 36 (4/11) / CNTN4, IL5RA, TRNT1+,
LRRN1
RP11–198G24b 3q26.1 165.27 57 (8/14) / No genes
RP11–108H14 4p14 36.99 6 (1/15) 55 (5/9) CENTD1, TBC1D1, PTTG2
RP11–63E13 4q13.3 66.42 / 66 (6/9) AF307080, EPHA5, CENPC1
RP11–117B11a 4q13.3 73.38 38 (5/13) / GC, GPR74, ADAMTS3
RP11–88E14 6p22.3 16.49 46 (6/13) / MYLIP, GMPR, ATXN1
RP11–163E21 6p22 16.76 60 (6/10) 33 (3/9) ATXN1
RP11–15111 11p14 23.93 40 (6/15) 20 (2/10) HTATIP2, HRMT1L3, SLC6A5,
NELL1,
TMEM16E, SLC17A6, FANCf,
GAS2, MUC15
RP11–439G16a,c 12p13.1 14 / 60 (6/10) RAI3, GPRC5D, HEBP1, GSG1,
EMP1, GRIN2B, ATF7IP,
GUCY2C
RP11–1092P21a,c 12p13.1 14.1 / 70 (7/10)
RP11–72J9a 12p13.1 14.4 / 66 (6/9)
RP11–92H16 12p12.1 21.7 7 (1/13) 57 (4/7) LDHB, KCNJ8, ABCC9
RP11–59N23 12p12.1 21.64 14 (2/14) 55 (5/9)
RP11–709A23 12p11.23 27.7 45 (5/11) 71 (5/7) PPFIBP1
RP11–12P7 14q22 52.12 7 (1/13) 60 (6/10) ERO1l, PSMC6, STYX; GNPNAT1,
PLEKHC1, DDHD1
RP11–814C11 19q13.31 49.81 36 (4/11) / PVR+
Genes residing between the two ﬂanking clones of losses are in italics, and with bolded characters for those mapping within clones. Gray-shaded
rows indicate clones of the chromosome 19 full-coverage array. Chromosome 10 clones were not included in the frequency analysis because most of
the GBM cell lines analysed lost the entire chromosome. aClones falling in SRO (Table 1) and in peaks of loss in quantitative analysis of
chromosome 10 (Figure 2). bClones/genes identiﬁed as polymorphic loci in the Genome Variation Database (http://projects.tcag.ca.variation).
cHomozygously and high-frequency heterozygously deleted clones.
Table 2 Homozygous deleted clones (log2 ratio o0.8)
Clone name Chr. band Mb position Cell line Annotated genes
RP11-67J2 2q22.3 145.24 1 (G1) HNMT, NXPH2, LRP1B, KYNU,
ARHGAP15, ZFHX1B
RP11-14G17 6q16.2 99.73 1 (MI-7) FTU9, FHL5, GPR63, KIAA1900,
POU3F2, FBXL4, COQ3, CCNC,
PRDM13
CTD-2097K16 9p21.3 21.95 2 (MI-7; MI-4) CDKN2A
RP11-79C22 10p14 7.34 1 (MI-4) SFMBT2, ITIH5, ITIH2, KIN,
ATP5C1, TAF3
RP11-45P20a 10q22.3 78.69 1 (MI-4) KCNMA1+
RP11-131C15 10q22.3 80.96 1 (MI-4) SFTPA2, SFTPA1, FAM22A,
SFTPD, ANXA11
RP11-129G17 10q23 90.17 1 (MI-60) PTEN
RP11-32H11a 10q26.2 128.72 1 (MI-63) CTBP2, MMP21, UROS, BCCIP,
DHX32,FANK1, ADAM12, DOCK1,
PTPRE, MKI67
RP11-48A2 10q26.2 129.80 1 (M-63)
14 clonesa 12p12.1–p13.32 1 (G32) —
RP11-3P8 13q34 111.75 1 (MI-7) ING1, ANKRD10, ARHGEF7, SOX1,
TUBGCP3
RP11-109J21 16q12.1 54.78 1 (T63) CES1, GNAO1, AMFR, CPSF5,
BBS2, Metallothioneins family1,
SCL12A3, HERPUD1, CETP,
CPNE2, ARL2BP, NIP30,
TMASF11
RP11-151M3 22q13.31 46.10 1 (MI-60) TAFA5
RP11-354I12 22q13.32 47.48 1 (MI-60)
RP11-179L12 22q13.33 47.82 1 (MI-60)
Genes residing between the two ﬂanking clones of losses are in italics, and with bolded characters for those mapping within clones. Chromosome 10
clones were not included in the frequency analysis because most of the GBM cell lines analysed lost the entire chromosome. aClones falling in SRO
(Table 1) and in peaks of loss in quantitative analysis of chromosome 10 (Figure 2).
Array-based CGH in glioma cell lines
G Roversi et al
1577
Oncogene
Discussion
This study reports on an application of high-resolution
aCGH to a consistent panel of well-characterized
primary glioma cell lines, by means of a 3.5k whole
genome plus full-coverage chromosome 19 BAC array.
Aiming at the identiﬁcation of recurrent genomic
aberrations involved in glioma genesis and/or progres-
Table 5 Most frequently gained clones with log2 ratio >0.3
Clone name Chr. band Mb position % non-GBM % GBM Genes
RP11-218I24 4q28.3 138.24 40 (6/15) / PCDH18, SLC7A11
RP11-80L16a,b 6q12 67.14 64 (9/14) 60 (6/10) EGFL11
RP11-17O4 9q34.2 125.76 40 (6/15) 33 (3/9) More than 30 genes in the interval
RP11-39G12c 11p11.2 46.58 50 (6/12) 50 (5/10) SYT13, CHST1, SLC35C1, CRY2,
MAPK8IP1, PEX16, BHC80,
CREB3L1, DGKZ, MDK,
CHRM4, ARHGAP1, ZNF408,
F2, ch-TOG, LRP4, MGC470,
PACSIN3, DDB2, ACP2, NR1H3,
IG20, MYBPC3, SPI1, PSMC3
RP11-79A4a,b,c 11p11.2 48.64 61 (8/13) 33 (3/9) PTPRJ, FOLH1, OR family
1129C9 19qter 64 57 (8/14) 33 (3/9) ZNF584, ZNF132, ZNF324,
SLC27A5, ZNF499, TRIM28,
UBE2M, ZNF42
RP11-598E05b 19p13.2 8.69 66 (10/15) 50 (5/10) OR2Z1, MBD3L1
RP11-1143D24a 19q12 32.59 33 (5/15) 60 (6/10) No genes
CTD-2001O24 19 43.4 26 (4/15) 66 (6/9) SIPA1L3, DPF1
RP11-79A22 19q13.3 50.09 6 (1/15) 60 (6/10) CEAL1, BCL3, CBLC, LU,
PVRL2, TOMM40, APOE,
APOC1, APOC4, APOC2,
CLPTM1, RELB, SFRS16 ,
ZNF342, GEMIN7, XTP7,
MARK4, CKM, KLC2L, ERCC2,
PPP1R13L, ASE-1, ERCC1,
FOSB
Genes residing between the two ﬂanking clones of losses are in italics, and with bolded characters for those mapping within clones. Gray-shaded
rows indicate clones of the chromosome 19 full-coverage array. Chromosome 7 clones are not included in Table 5 as most GBM cell lines gained the
entire chromosome with values ﬁtting log2 ratio >0.3.
aHigh-frequency gained clones with both log2 ratio >0.5 and >0.3.
bClones/genes identiﬁed
as polymorphic loci in the Genome variation Database (http://projects.tcag.ca.variation). cClones falling in SRO (Table 1).
Table 4 Most frequently gained clones with log2 ratio >0.5
Clone name Chr. band Mb position GBMs Genes
RP11-172G5 3q26.3 174.54 3 of 10 ECT2, SPATA16, NLGN1
RP11-123E5 7p21 17.33 3 of 9 TM4SF13, AHR
RP11-87M15 7p14 36.47 3 of 10 AOHA , ELMO1
RP5-953A4 7q11.23 74.59 4 of 9 More than 15 genes plus WBSCR20B,
PMS2L2
RP11-49N15 7q21.3 92.53 3 of 10 CALCR
RP11-72J24 7q22.3 104.20 3 of 10 PRES, RELN, ORC5L, MLL5+,
SYPL, PBEF1, PIK3CG
RP11-148F17 7q33 136.66 3 of10 DGK1
RP11-43L19 7q36.2 150.93 3 of 10 ABCF2, SMARCD3, NYREN18,
RHEB, PRKAG2, GALNT5–11,
MLL3, XRCC2
RP1-3K23a 7qter 157 4 of 10 PTPRN2, VIPR2
RP11-93H24 13q14.3 52.11 3 of 10 SUGT1LECT1, LECT1
RP11-1143D24 19q12 32.50 3 of 10 No genes
Clone name Chr. band Mb position Non-GBMs Genes
RP11-80L16a 6q12 67.14 4 of 14 EGFL11
RP11-79A4a,b 11p11.2 48.64 3 of 14 PTPRJ, FOLH1, OR family
RP11-598E05a 19p13.2 8.69 5 of 15 OR2Z1, MBD3L1
RP11-1143D24 19q12 32.50 3 of 15 No genes
Genes residing between the two ﬂanking clones of losses are in italics, and with bolded characters for those mapping within clones. Gray-shaded
rows indicate clones of the chromosome 19 full-coverage array. aClones falling in SRO (Table 1). bClones/genes identiﬁed as polymorphic loci in the
Genome variation Database (http://projects.tcag.ca.variation).
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sion towards the highest malignancy grade (WHO grade
IV), we systematically compared copy number changes
in GBM (WHO grade IV) versus non-GBM cell lines,
which included low-grade gliomas (WHO grade I and
II) and anaplastic gliomas (WHO grade III). In this
context, we took two different and complementary
interpretative approaches. The ﬁrst one is based on
single clone frequency analysis, and aims at the
deﬁnition of the smallest consistently affected intervals
of copy number changes. In addition, in order to deﬁne
clustered clones in consecutive areas of chromosomal
imbalance, data analyses was aided by the use of a
second, extensive statistical approach known as ‘MA
approach’ (Schraders et al., 2005). This approach is
considered an important tool to unmask single-copy
changes which log2 ratio values might be underscored
particularly in tumors, like gliomas, characterized by
high cellular and genetic heterogeneity and ploidy
aberrations (Noble and Dietrich, 2004).
In large-scale studies of tumors such as gliomas, for
which primary material is hardly ever available for other
than diagnostic purposes, primary cell lines have always
been considered a good model while studying glioma-
genesis (Fischer et al., 1985; Bigner et al., 1987; Rey
et al., 1989; Bakir et al., 1998). Even with the advent of
high-resolution techniques, such as aCGH, a remark-
able concordance of ﬁndings has repeatedly been
demonstrated, with only minute differences, between
early passage glioma cell lines and corresponding
original tumors (Cowell et al., 2004b). Also, the aCGH
data on glioma cell lines presented here conﬁrm the
known gross aberrations detected on glioma samples by
conventional CGH and LOH analyses, such as þ 7, 10
and 22q, thereby further supporting the reliability of
cell lines as research tools in cancer genetics of gliomas.
aCGH data processed by the MA approach facilitated
the identiﬁcation of small genomic regions of copy
number changes, all representing novel ﬁndings in
gliomas, with the exception of the gained region detected
in GBMs at 1q32.1, which indeed represents a well-
known ampliﬁcation target in malignant gliomas (Rie-
menschneider et al., 2003). Of particular interest because
of their speciﬁcity to one of our two glioma groups are
losses detected in GBMs at 4p16.1, and in non-GBMs at
3p26.1–p26.3, 4q13.2–q21.1 and 7p15.3–p21.1. In parti-
cular, losses mapping at the 3p26.1–p26.3 SRO were
shared by 8/15 non-GBM cell lines, and were never
observed in GBM cell lines. A correlation between 3p
losses and low-grade gliomas has been observed in the
past in studies focusing on 3p LOH demonstrating that
40% low-grade gliomas showed 3p LOH, while reten-
tion of 3p heterozygosity correlated with high patholo-
gical grade: accordingly, patients with 3p LOH had a
signiﬁcantly longer survival time than those without
LOH (Kanno et al., 1997).
In contrast, the remaining SROs we detected at 4p15.31–
p15.32, 5q22.2–q23.3, 6p23–p25.3, 11p11.2–q13.2 and
12p13.1–p13.2 are shared by GBMs and non-GBMs, even
though some appear to prevail in one of the two groups.
Particularly, we observed high deletion frequencies for an
SRO mapping to 12p13.1–p13.2, which was found to be
lost in three non-GBMs and ﬁve GBMs. Single clone
analyses also pointed out the involvement of three clones
contained in the 12p SRO in at least six GBM lines (60%).
12p has previously been described as site of gain events in
gliomas (Weber et al., 1996), with ampliﬁcations targeting
the CCND2 gene at 12p13.32 (Buschges et al., 1999). Our
results do not conﬁrm gain/ampliﬁcation of this locus, but
are consistent with the mapping within the 12p SRO of a
12p tumor suppressor locus that has been postulated to be
involved in a wide range of hematological malignancies
and solid tumors (Montpetit et al., 2002).
The 11p11.2–q13.2 SRO gained region is observed in
three non-GBMs and three GBMs. The RP11-39G12
clone residing within this SRO shows a high gain
frequency in non-GBMs and GBMs (both 50%).
Several interesting genes map in the affected interval.
Among these, the neurite growth-promoting factor
MDK has very recently been found ampliﬁed in a
GBM specimen by aCGH analysis (Cowell et al.,
2004b). DDB2, a DNA repair protein, is involved
in the crossresistance of cisplatin-selected cell lines to
death ligand-mediated apoptosis (TNF-alpha and
Fas-inducing antibody). It functions as a negative
regulator of apoptosis because overexpression of
DDB2 suppresses TNF signaling-mediated apoptosis
(Sun and Chao, 2005). Therefore, DDB2 may have a
pivotal role in regulating efﬁcacy of anticancer drugs
like TRAIL (TNF-related apoptosis-inducing ligand), a
promising death ligand for glioma treatment (Hawkins,
2004).
Also the IG20 gene, which appears to have at least
seven splice variants, encodes for a protein involved in
the TNF-alpha signaling pathway; overexpression of its
isoform DENN-SV, the only one expressed in normal
brain, enhances cell replication and resistance to TNF-
alpha, vinblastine, etoposide and g-radiation, support-
ing the antiapoptotic and cell survival role of DENN-SV
(Eﬁmova et al., 2004).
In addition, aCGH in combination with the MA
approach enabled us to further reﬁne known loci
involved in glioma progression, such as, for instance,
those on chromosome 10. In GBM, loss of chromosome
10 is the most frequently reported genetic event,
commonly accounted for by the presence of tumor
suppressors on both 10p and 10q. On 10p, the most
frequent site of LOH involves band 10p15 (Harada
et al., 2000), whereas for the q arm, known or putative
tumor suppressor genes as PTEN (10q23), LGI1 (10q24)
and DMBT1 (10q26) are affected in only 30% or less of
GBMs, suggesting the presence of additional tumor
suppressors genes. More particularly, the 10q25–26
region has been referred to as a target of allelic loss in
the majority of GBMs and theWRD11 gene (10q26) has
been proposed as a prime positional candidate gene
(Chernova et al., 2001).
The ‘MA’ data analysis of our GBM cell line panel
conﬁrmed both the above-mentioned ‘hotspots’ on
chromosome 10 as deletion targets and pointed out
three main peaks of most extreme values at 10p15.3,
10q22.3 and 10q26.13–q26.2. The evidence that these
peaks do not include the most known candidate genes
Array-based CGH in glioma cell lines
G Roversi et al
1579
Oncogene
led us to assume that other tumor suppressor genes with
a critical role in the context of glioma progression might
reside within these identiﬁed intervals. Interestingly,
only the ADARB2 gene, a brain speciﬁc deaminase,
resides within the 10p15.3 interval. The BBCIP
(10q26.6) gene maps within the 10q26.13–q26.2 peak
and is among the genes in the interval encompassed by
clone RP11-32H11, which is homozygously deleted in
the MI-63 cell line. This gene encodes a protein
interacting with BRCA2 and CDKN1A (p21), which
participates in DNA repair and cell cycle control. It has
been shown that the BBCIP beta form inhibits cell cycle
progression from G1 to S (Meng et al., 2004), while its
alpha form inhibits brain cancer cell growth, conﬁrming
a role as candidate tumor suppressor in brain tumors
(Liu et al., 2001) as well as in other tumor types (Meng
et al., 2003).
With regard to chromosome 19, which was inter-
rogated with a full-coverage/tiling path resolution array,
one out of the six gliomas with oligodendroglial
components and none of the 19 astrocytomas showed
deletions at 19q13.3, the well-known LOH area in
gliomas, lacking so far any identiﬁed tumor suppressor
gene (Hartmann et al., 2002). It has been recently
demonstrated by aCGH that 19q LOH in oligoden-
drogliomas and mixed OA is due to physical loss of
genetic material rather than to genetic events as mitotic
recombination (Cowell et al., 2004a; Kitange et al.,
2005). Our data raise the question whether or not in
astrocytic tumors 19q LOH involves the same region
and is caused by the same mechanisms as in tumors
containing oligodendroglial components.
We previously reported that the novel serine threo-
nine kinase MARK4 gene at 19q13.32 is duplicated in
three GBM cell lines, which were also present in the
panel used for this study (MI-4, GBM and MI-7)
(Beghini et al., 2003). By means of the MA algorithm,
we found that MARK4 resides within the region of gain
in three non-GBMs and in the GBM cell line MI-4. On
the contrary, no gains were detected for cell lines GBM
and MI-7.
However, the duplication of MARK4 we previously
described by FISH analysis was characterized through
the use of a much smaller contig containing 10 cosmids,
of which LLNL-R31237, only containingMARK4 gene,
turned out to be duplicated (Beghini et al., 2003). On the
other hand, the tiling BAC clones array covering
entirely MARK4 gene span a region containing genes
other than MARK4. As only the minimal MARK4
region is duplicated, this would indeed translate into a
small fraction of the BAC clones being gained, leading
to a very subtle increase in signal intensity. Conse-
quently, we presume that the lack of detection of
MARK4 duplication by aCGH in the above cell lines
might be due to the different genomic content of the
probes used in these analyses. Interestingly, the MA
data analysis highlighted two main gained regions, never
before described in gliomas, and mapping to 19p13.11
and 19q13.13–13.2; however, currently no known
oncogene has been identiﬁed in either one of these two
intervals.
Single clone analysis facilitated the identiﬁcation of
very subtle regions not included in the SROs, which, due
to their small size, could be directly translated into a
limited number of corresponding, and possibly causative
genes. Some of these, manifesting as homozygous
deletions and found only in GBM cell lines point at
tumor suppressor genes including PTEN (10q23), p16
(9p21.3) and ING1 (13q34) (Zhu and Parada, 2002;
Collins, 2004; Tallen et al., 2004), which have previously
associated with glioma progression. Others are known
as putative tumor suppressor genes involved in other
cancer types. For instance, LRP1b (2q22.3) has been
postulated to play an important role in the tumorigen-
esis of lung cancer (Liu et al., 2000), but is expressed
predominantly in the brain (Marschang et al., 2004).
The fact that we reidentiﬁed some of these widely
acknowledged causative genes in our opinion once more
conﬁrms the validity of our approach.
Interestingly, PRDM2, a tumor suppressor gene
highly expressed in brain tumors (Muraosa et al.,
1996), represents one of the two genes within the
interval of the clone RP11-178M15 at 1p36.21, exclu-
sively lost in 35% of non-GBMs.
Three GBMs showed ampliﬁcations at 3q26.3 poten-
tially involving the epithelial-transforming factor
(ECT2) proto-oncogene, for which an involvement in
brain tumors has never been suggested before.
In our cell lines, we did not detect ampliﬁcation of the
EGFR gene at 7p11.2, which is found in approximately
40% of primary, but rarely in secondary GBMs (Zhu
and Parada, 2002; Collins, 2004). The lack of this
ﬁnding could be related to the low number in our panel
of primary GBMs with an overt de novo diagnosis (ﬁve
of 10 GBMs), and/or to culture conditions, in line with
published data suggesting a selection for ampliﬁed
EGFR in vivo and a selection against EGFR ampliﬁca-
tion in vitro (Pandita et al., 2004) also in early passage
cultures (Cowell et al., 2004b).
Further validation focusing on the above-mentioned
data will be a necessary step to strengthen the candidate
regions and genes within or nearby the clones sorted out
from our study, and future research might clarify their
potential functional role in glioma genesis and/or
progression.
The overall achieved insights and their implications
increase our current knowledge about subtle genetic
changes in gliomas and may facilitate further identiﬁca-
tion of novel genetic elements, which are of importance
in the onset and/or progression of glial tumors.
Deﬁnition of the multiplicity of genetic elements
involved in gliomagenesis provides us with the necessary
background needed for the design of novel molecular
tools that can be used for an improved diagnostics/
therapeutic decision-making in gliomas.
Material and methods
Glioma cell lines
Primary cell lines used for this study included one pilocytic
astrocytoma (WHO grade I), ﬁve astrocytomas of grade II
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including three mixed OAs, nine anaplastic astrocytomas
(WHO grade III) including three mixed AOAs, all classiﬁed by
us as ‘non-GBMs’, and 10 gliomas of grade IV (GBMs).
Within grade IV, four de novo (primary) GBMs, one secondary
(arisen from a previous astrocytoma) GBM, three apparently
secondary GBMs (based on tumoral differentiated areas
within the specimen, but not attested by previous surgery or
anamnesis), one primary giant cell and one apparently
secondary giant cell GBM are included.
Primary glioma cell lines were established from biopsy
fragments using methods described previously (Magnani et al.,
1994). The GBM (Perego et al., 1994) and MI-4 (Magnani
et al., 1994, 1999, 2005) cell lines were used at 33rd and 61st
passage, respectively, whereas all other cell lines were used
before their 14th passage. All cell lines were maintained in
RPMI 1640 medium containing 5% FCS at 371C and 5% CO2.
WHO classiﬁcation, clinical data and cytogenetic analysis of
the fresh tumors of origin, when available, are provided in
Supplementary Table A. All karyotypes were described
according to ISCN 95 guidelines (Mitelman, 1995).
Additional karyotyping was performed on MI-4, MI-60
(Magnani et al., 1999), GBM and MI-7 (Magnani et al., 1999)
cell lines at the ﬁrst passages. The ﬁrst three cell lines presented
the same stemline karyotype described primarily, whereas the
karyotype of MI-7 revealed a subclone containing 59 chromo-
somes in addition to the original tumor (46, X, Y, þ 7/59,
XY, þ 1, þ del(3q) 2, 4, þ 5, þ 6, þ 7, þ 7, þ 7, add9q34,
12, 13, þ 16, þ 19, þ 20, þ 21, þ 21, þ 1).
Array-based CGH
aCGH hybridizations were performed on microarrays contain-
ing approximately 4300 BAC clones. These BAC clones can be
subdivided in approx. 3600 BAC clones that are equally
distributed over the entire human genome with an average
800 kb resolution (Schraders et al., 2005) and approx. 700
BAC clones that cover close to the entire chomosome 19 at
tiling path resolution. For chromosome 19, a full-coverage set
containing approc. 700 chromosome-speciﬁc, ﬁnger-printed
and phage-tested BAC clones was selected from a larger ‘32k
set’, which was developed at the British Columbia Cancer
Agency Genome Sciences Center, Vancouver, Canada (Krzy-
winski et al., 2004). This subset covers chromosome 19 with an
average resolution of 100 kb. Preparation of BAC arrays,
labeling and hybridizations were performed essentially as
described by Vissers et al. (2003). All hybridizations were
performed on the same batch of quality controlled arrays,
thereby excluding minor batch-to-batch differences.
Analysis of the microarray images obtained from the BAC
hybridizations was performed using the software package
GenePix Pro 4.0 (Axon Instruments Inc., Foster City, CA,
USA). For each spot, the median pixel intensity minus the
median local background for both dyes was used to obtain a
genomic copy number ratio. Data normalization was per-
formed in the software package SAS version 8.0 (SAS Institute
Inc.) for each array subgrid, by applying Lowess curve ﬁtting
with a smoothing factor of 0.3 to predict the log2-transformed
test-over-reference (T/R) value on the basis of the average
logarithmic ﬂuorescent intensities (Cleveland, 1979). All
mapping information regarding clone locations, cytogenetic
assignments and gene content were retrieved from the UCSC
human genome browser (http://genome.ucsc.edu/, May 2004
freeze).
Statistical analysis
To detect areas of nonoverlapping gained and lost consecutive
clones, we applied an algorithm that we have recently described
(Schraders et al., 2005) based on extreme values of MAs of
normalized log2 ratios with different window sizes. Mathema-
tical/statistical details underlying this algorithm are available
upon request (H.straatman@epib.kun.nl). The most extreme
MA in all cell lines was above þ 0.1 or below 0.1, with the
exception of two areas, one at 3p and the other at 7p (the most
centromeric) (Figure 1), both with a mean of 0.09 with a
window width of 24 and 27 clones, respectively. The MA
algorithm was used in six normal versus normal hybridizations
to identify false-positive areas caused by underperformance of
individual clones or novel polymorphic regions/large-scale copy
number variations (LCVs). All areas of copy number changes
identiﬁed in cell line samples by MAs with a window width
from 2 to 10 were excluded even if present only once in normal
versus normal hybridizations, and the same approach was
adopted for MAs with a window width from 11 to 30. The only
exception was one deleted interval at 4p, where in normal
versus normal hybridizations three extremeMAs were detected:
the ﬁrst, with a mean of 0.22 and a window width of eight
clones in cell line samples showed higher mean values ranging
from 0.35 to 0.57. The other two extreme MAs, with a
window width from 11 to 30, showed a mean of 0.14 and
0.17 in normal versus normal hybridizations. Therefore, we
included in the analysis only MAs with a window width from
11 to 30 below 0.3 in cell line samples.
For whole chromosome association analysis, a chromosome
was scored as gained or lost when: (a) 90% of all clones on the
chromosome had a log2 ratio > or o0, respectively; (b) the
median of the log2 ratio of all clones on that chromosome was
> or o0.1 or 0.1, respectively (Hackett et al., 2003).
Samples were hybridized in sex-mismatch hybridization
schemes, allowing for a quick objective general assessment of
the quality of individual experiments by determination of
average normalized T/R values for the sex chromosomes. For
this reason, sex chromosomes were excluded for further
analysis.
Single clone analysis
As a ﬁrst step, ‘suspicious clones’, which were deﬁned as clones
that have either a standard deviation >0.26 or o0.026 or a
z-value (average ratio/standard error) >5 in the normal versus
normal hybridizations (references), were discarded. In addition,
clones showing a standard deviation d>0.3 over triplicate in
the individual experiments were excluded, as well as clones with
less than two replicates remaining after this analysis.
Subsequently, copy number changes were scored as gains or
losses when the normalized mean log2 (test/reference) ratio
was >þ 0.3 or o0.3, respectively. These boundaries were
arbitrarily set by examining the results of the normal versus
normal hybridizations and supported by the results of
previously published work (Veltman et al., 2003a, b; Vissers
et al., 2003). To detect hotspots of genomic imbalances, we
excluded from the analysis clones showing copy number
changes in one or more of the six normal versus normal
hybridizations. We subsequently established a ‘threshold of
signiﬁcance’, including in the analysis only informative clones
in at least 5/6 normal versus normal, 10/15 ‘non-GBMs’ versus
normal and 7/10 ‘GBMs’ versus normal hybridizations. Clones
of interest were selected on the basis of the highest frequencies
of aberration calculated on informative clones in either ‘non-
GBM’ or GBM specimens.
All information regarding physical maps and genomic
content of clones was obtained through the UCSC human
genome browser (http://genome.ucsc.edu/, May 2004 freeze),
and clones were queried as possible LCVs or CNPs (copy
number polymorphisms) at the Genome Variation Database
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(http://projects.tcag.ca.variation) (Iafrate et al., 2004; Sebat
et al., 2004).
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